GlaxoSmithKline Pharmaceuticals Ltd stock PB Ratio (=17.43) is close to 2-year low of 15.84.
The historical rank and industry rank for GlaxoSmithKline Pharmaceuticals's PB Ratio or its related term are showing as below:
NSE:GLAXO'
s PB Ratio Range Over the Past 10 Years
Min: 9.32 Med: 16.8 Max: 30.02
Current: 17.6
During the past 13 years, GlaxoSmithKline Pharmaceuticals's highest PB Ratio was 30.02. The lowest was 9.32. And the median was 16.80.
NSE:GLAXO's PB Ratio is ranked worse than 96.2% of 922
companies
in the Drug Manufacturers industry
Industry Median: 1.825
vs NSE:GLAXO: 17.60
During the past 12 months, GlaxoSmithKline Pharmaceuticals's average Book Value Per Share Growth Rate was 16.20% per year.
During the past 3 years, the average Book Value Per Share Growth Rate was 9.20% per year.
During the past 5 years, the average Book Value Per Share Growth Rate was 3.60% per year.
During the past 10 years, the average Book Value Per Share Growth Rate was -0.40% per year.
During the past 13 years, the highest 3-Year average Book Value Per Share Growth Rate of GlaxoSmithKline Pharmaceuticals was 18.20% per year. The lowest was -10.40% per year. And the median was 4.00% per year.
Back to Basics: PB Ratio
GlaxoSmithKline Pharmaceuticals (NSE:GLAXO) PB Ratio Explanation
The PB Ratio works the best for the businesses that earn most of their profit from their assets, e.g. banks and insurance companies.
Be Aware
Some businesses have very light assets, such as software companies or insurance agencies. The PB Ratio does not work well for these companies. Some companies even have negative equity, so the PB Ratio cannot be applied to them.
GlaxoSmithKline Pharmaceuticals PB Ratio Related Terms
GlaxoSmithKline Pharmaceuticals PB Ratio Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - General subindustry, GlaxoSmithKline Pharmaceuticals's PB Ratio, along with its competitors' market caps and PB Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
GlaxoSmithKline Pharmaceuticals PB Ratio vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, GlaxoSmithKline Pharmaceuticals's PB Ratio distribution charts can be found below:
* The bar in red indicates where GlaxoSmithKline Pharmaceuticals's PB Ratio falls into.
GlaxoSmithKline Pharmaceuticals PB Ratio Calculation
The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. It is a ratio widely used to value stocks.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
It can also be calculated from the numbers for the whole company:
A closely related ratio is called Price-to-Tangible-Book. The difference between Price-to-Tangible-Book and PB Ratio is that book value other than intangibles are used in the calculation.
GlaxoSmithKline Pharmaceuticals (NSE:GLAXO) has a PB Ratio of 17.59 as of Jun. 26, 2026. Price-to-Book ratio is the ratio of share price to a company's book value per share. View historical data on GlaxoSmithKline Pharmaceuticals and its competitors. This is near median its historical median of 16.80. Over the past decade, GlaxoSmithKline Pharmaceuticals' PB Ratio has ranged from 9.32 to 30.02. According to the industry distribution chart, GlaxoSmithKline Pharmaceuticals ranks #887 out of 922 companies in the Drug Manufacturers industry, placing it in the top 96.2%.
Is GlaxoSmithKline Pharmaceuticals' PB Ratio too high?
GlaxoSmithKline Pharmaceuticals' current PB Ratio of 17.59 is near median its 10-year median of 16.80. Over the past 10 years, this metric has ranged from a low of 9.32 to a high of 30.02. The Drug Manufacturers industry median PB Ratio is 1.83. GlaxoSmithKline Pharmaceuticals' value of 17.59 is 863.8% above this industry median. Based on the distribution chart, GlaxoSmithKline Pharmaceuticals ranks #887 out of 922 companies in the Drug Manufacturers industry, which is in the bottom quartile relative to peers. Overall, GlaxoSmithKline Pharmaceuticals has a GF Score™ of 73/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does GlaxoSmithKline Pharmaceuticals' PB Ratio compare to LLY and JNJ?
According to the Drug Manufacturers industry distribution chart, GlaxoSmithKline Pharmaceuticals ranks #887 out of 922 companies for PB Ratio. This places GlaxoSmithKline Pharmaceuticals in the lower half of its industry. The industry median PB Ratio is 1.83. GlaxoSmithKline Pharmaceuticals' value of 17.59 is 863.8% above this benchmark. Historically, GlaxoSmithKline Pharmaceuticals' own PB Ratio has ranged from 9.32 to 30.02 over the past decade. While the company's 10-year median is 16.80 vs. the industry median of 1.83, GlaxoSmithKline Pharmaceuticals has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good PB Ratio for a Drug Manufacturers company?
The median PB Ratio among Drug Manufacturers companies is 1.83, based on 922 companies in the industry. Companies in the top quartile (top 25%) have a PB Ratio significantly above this median, while those in the bottom quartile fall well below. However, PB Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. GlaxoSmithKline Pharmaceuticals's current PB Ratio of 17.59 is 863.8% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high PB Ratio mean?
A high PB Ratio can signal that a stock is expensive relative to its fundamentals. Price-to-Book ratio is the ratio of share price to a company's book value per share. View historical data on GlaxoSmithKline Pharmaceuticals and its competitors. For the Drug Manufacturers industry, the median PB Ratio is 1.83 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. GlaxoSmithKline Pharmaceuticals's current PB Ratio is 17.59, which is near median its own 10-year median of 16.80. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is GlaxoSmithKline Pharmaceuticals stock overvalued right now?
Based on GuruFocus' analysis, GlaxoSmithKline Pharmaceuticals (NSE:GLAXO) is currently considered Modestly Undervalued. The stock's GF Value™ is ₹2,614.23, compared to a current price of ₹2,354.80 — trading 9.9% below its estimated fair value. The current PB Ratio is 17.59, which is near median its 10-year median of 16.80 and 863.8% above the Drug Manufacturers industry median of 1.83. GlaxoSmithKline Pharmaceuticals' overall GF Score™ is 73/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is PB Ratio calculated?
PB Ratio is calculated from a company's financial statements. For GlaxoSmithKline Pharmaceuticals (NSE:GLAXO), the current PB Ratio is 17.59 as of Jun. 26, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is GlaxoSmithKline Pharmaceuticals (NSE:GLAXO) Overvalued in 2026?
Based on GuruFocus' analysis, GlaxoSmithKline Pharmaceuticals stock appears to be undervalued.
The current stock price of ₹2,354.80 is trading 9.9% below its estimated GF Value™ of ₹2,614.23.
GuruFocus considers GlaxoSmithKline Pharmaceuticals to be Modestly Undervalued.
Key valuation signals for NSE:GLAXO:
PB Ratio: 17.59 (near median its 10-year median of 16.80)
GF Value™: ₹2,614.23 vs. price of ₹2,354.80 (9.9% below fair value)
Industry Position: 863.8% above the Drug Manufacturers median (#887 of 922)
No single metric tells the full story. See the NSE:GLAXO stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
GlaxoSmithKline Pharmaceuticals Business Description
GlaxoSmithKline Pharmaceuticals Ltd is engaged interalia, in the business of manufacturing, distributing and trading in pharmaceuticals. It is healthcare organisation focused on uniting science, technology and talent to get ahead of disease. The company's product portfolio comprises a broad range of General Medicines which includes anti-infectives, pain management, vitamins, minerals, nutritionals, hormones, dermatologicals, vaccines for both children and adults, and specialty medicines for respiratory and oncology. Its focused brands are Augmentin, Ceftum, Flutivate, T-bat, Betnovate, Neosporin, Tenovate, Physiogel, Calpol and Calpol T. The company has single reportable segment. The company has presence in India, and also Outside India. It generates majority of revenue from India.
73GF Score
Get the complete analysis for NSE:GLAXO
PB Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
NSE:GLAXO has been successfully added to your 
